Comparison of Serum Potassium, MagnEsium, and Calcium Levels between Kanamycin and Capreomycin-BASEd Regimen-Treated MultiDrug-Resistant TuBerculosis Patients in Bandung (CEASE MDR-TB): A Retrospective Cohort Study
Authors:
Open Access
- 14 March 2019
- journal article
- research article
- Published by Wiley in International Journal of Microbiology
- Vol. 2019, 1-7
Abstract
Treatment of multidrug-resistant tuberculosis (MDR-TB) with second-line injectable drugs may result in an electrolyte imbalance. This retrospective study was performed to compare and evaluate the effect of kanamycin and capreomycin on serum potassium, calcium, and magnesium in the first and second month treatment at a tertiary, top-referral hospital in Bandung, Indonesia. Data from 84 subjects with complete medical records of at least serum potassium during either kanamycin-based or capreomycin-based treatment were retrieved from the institutional database. Among these, 53 subjects had complete serum calcium data and 53 subjects had complete serum magnesium data. After the first month of MDR-TB treatment, there was a significant decrease in mean serum potassium (4.0 ± 0.4 mEq/L to 3.7 ± 0.5 mEq/L, ) in the kanamycin-based group and (4.1 ± 0.5 mEq/L to 3.2 ± 0.6 mEq/L, ) in the capreomycin-based group. Serum potassium levels were significantly lower in the capreomycin-based group than in the kanamycin-based group (3.2 ± 0.6 mEq/L vs 3.7 ± 0.5 mEq/L, ). The incidence of hospitalization and requirement for a change in the treatment regimen due to electrolyte imbalances were higher in the capreomycin-based group. No previous longitudinal study has evaluated serum potassium, magnesium, and calcium from the first month of MDR-TB treatment with either kanamycin-based or capreomycin-based regimens. Our findings emphasize the importance of routine monitoring of serum potassium, magnesium, and calcium during MDR-TB treatment, and that more attention should be paid when treatment is given using the capreomycin-based regimen. Moreover, our study supported the 2018 World Health Organization treatment guideline recommendations for removal of kanamycin and capreomycin from the MDR-TB regimens.
Keywords
This publication has 22 references indexed in Scilit:
- The Antituberculosis Antibiotic Capreomycin Inhibits Protein Synthesis by Disrupting Interaction between Ribosomal Proteins L12 and L10Antimicrobial Agents and Chemotherapy, 2014
- Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South AfricaPLOS ONE, 2013
- Medical Treatment of Pulmonary Multidrug-Resistant TuberculosisInfection & Chemotherapy, 2013
- Two unusual cases of severe recalcitrant hypocalcemia due to aminoglycoside-induced hypomagnesemiaIndian Journal of Endocrinology and Metabolism, 2013
- The Calcium-Sensing Receptor: A Molecular PerspectiveEndocrine Reviews, 2011
- Pathophysiology and management of hypokalemia: a clinical perspectiveNature Reviews Nephrology, 2011
- Agonists and Allosteric Modulators of the Calcium-Sensing Receptor and Their Therapeutic ApplicationsMolecular Pharmacology, 2009
- Reducing Routine Ionized Calcium MeasurementClinical Chemistry, 2009
- Hypokalemia Among Patients Receiving Treatment for Multidrug-Resistant TuberculosisChest, 2004
- Capreomycin-induced serum electrolyte abnormalitiesThorax, 1970